FibroBiologics, Inc. FBLG
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.29% | 17.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.42% | 95.68% | |||
| Operating Income | 20.42% | -95.68% | |||
| Income Before Tax | 17.66% | -54.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.66% | -54.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.66% | -54.13% | |||
| EBIT | 20.42% | -95.68% | |||
| EBITDA | 20.69% | -98.18% | |||
| EPS Basic | 50.47% | -22.92% | |||
| Normalized Basic EPS | 50.48% | -22.93% | |||
| EPS Diluted | 50.47% | -22.92% | |||
| Normalized Diluted EPS | 50.48% | -22.93% | |||
| Average Basic Shares Outstanding | 66.25% | 25.39% | |||
| Average Diluted Shares Outstanding | 66.25% | 25.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||